US › Healthcare

argenx NV ADR (ARGX)

US · Healthcare · Biotechnology

$844.50+1.65%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$2.82B
Revenue YoY
+197.0%
Net profit
$838.8M
Profit YoY
+241.9%
EPS
$7.32
EPS estimate
$6.13
Net margin
29.8%

EPS came in at 7.32 against a street estimate of 6.13 — a beat of 19.4%.

Key statistics

Market cap
$53.10B
P/E
32.6
Forward P/E
30.4
P/B
6.34
Book value
$5.38
EPS (TTM)
$26.21
52-week high
$953.58
52-week low
$631.47
50-day MA
$871.72
200-day MA
$830.04
Beta
-0.02

Analyst view

Analysts rate argenx NV ADR a strong buy (21 buy, 1 hold, 0 sell out of 22) with an average price target of $1,079.55.

Shareholding

Institutions
47.37%

Largest institutional holders

FundStake
FMR Inc7.98%
T. Rowe Price Associates, Inc.5.39%
HHG PLC4.06%
Capital World Investors3.61%
Artisan Partners Limited Partnership2.35%
Wellington Management Company LLP1.63%
venBio Select Advisor LLC1.60%
BlackRock Inc1.29%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for argenx NV ADR — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.